PubMed Health⌕ Search

PubMed · 10448117

Fusion genes in solid tumors.

Abstract

Tumor development in different cell types and tissue locations involves many pathways, distinct genes and exogenous factors. Tumor type-specific chromosome rearrangements resulting in fusion genes or promoter swapping are believed to be involved in the early development of many tumor types. They are present in almost all cases of a particular tumor type and cases have been described that carry only tumor type-specific translocations without any signs of other cytogenetic changes. The mechanisms behind chromosome rearrangements in solid tumors are largely unknown. Radiation is an important factor in thyroid carcinomas but no com-$bmon sequence motifs are made out in the break points of solid tumors. The fusion genes found in sarcomas are dominated by the transcription factor type of genes with the TLS/FUS and EWS series of fusion genes as the largest group. More than 50% of papillary thyroid carcinomas carry fusion proteins with tyrosine kinase activity. Rearrangements involving HMGIC, HMGIY, and PLAG1 are common in benign mesenchymal tumors and salivary gland adenomas. Many recurrent tumor translocations show a strict specificity for tumor type. This specificity can most likely be explained by the specific sets of target genes that are deregulated by the fusion gene products. Identification of the downstream target genes is currently the object of intense research and may provide us with information that will help design better diagnostic tools and eventually find a cure for these diseases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Aman. 1999. Fusion genes in solid tumors.. https://doi.org/10.1006/scbi.1999.0130

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The role of Shp2 (PTPN11) in cancer.

Tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs), regulates numerous cellular processes. Altered expression and/or mutations in PTKs are linked to many forms of cancer, yet until recently little was known about the roles of PTPs in normal cells or in cancer. Earlier work established that a member of the PTP superfamily, PTEN, is an important tumor suppressor gene. We now know that at least one other PTP, the SH2 domain-containing phosphatase Shp2, is a bona fide oncogene that is mutated in several types of leukemia and hyperactivated by other mechanisms in some solid tumors. Understanding how Shp2 and other PTPs contribute to oncogenesis should provide new insights into pathogenesis and might suggest new targets for anti-neoplastic drugs.

Gene Expression Regulation, Neoplastic↗

Jak2: normal function and role in hematopoietic disorders.

Janus kinase 2 (Jak2) associates with cytokine receptors and is essential for signal transduction by mediating tyrosine phosphorylation. Kinase activity is regulated by a series of interactions beginning with the requirement to bind to specific domains in receptors, suppression of activation by the pseudokinase domain, and the requirement for phosphorylation within the activation loop. Recent studies have implicated de-regulation of Jak2 kinase activity by chromosomal translocations in hematopoietic tumors and mutations within the pseudokinase domain in a spectrum of myeloproliferative diseases.

Gene Expression Regulation, Neoplastic↗

Transcription factors in hematopoietic malignancies.

Transcription factors comprise a high proportion of the proteins with dysregulated expression or altered activity in cancer cells. In recent years, great progress has been made in elucidating crucial pathways in leukemogenesis, partially by identifying key transcription factors that are normally indispensable for hematopoiesis but which are often associated with malignant transformation when functioning improperly. The significance of transcription factors is highlighted by the multiple mechanisms used by leukemic cells to abrogate their normal activity. Delineating these mechanisms can benefit the diagnosis and treatment of hematological malignancies and might also be applicable to certain solid tumors.

Gene Expression Regulation, Neoplastic↗